[go: up one dir, main page]

UY28098A1 - Derivados de anilinopirazol útiles en el tratamiento de la diabetes - Google Patents

Derivados de anilinopirazol útiles en el tratamiento de la diabetes

Info

Publication number
UY28098A1
UY28098A1 UY28098A UY28098A UY28098A1 UY 28098 A1 UY28098 A1 UY 28098A1 UY 28098 A UY28098 A UY 28098A UY 28098 A UY28098 A UY 28098A UY 28098 A1 UY28098 A1 UY 28098A1
Authority
UY
Uruguay
Prior art keywords
diabetes
anilinopirazol
derivatives
useful
treatment
Prior art date
Application number
UY28098A
Other languages
English (en)
Inventor
Joachim Rudolph
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Herbert Ogutu
Alan Olague
Ning Qi
Philip L Wickens
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of UY28098A1 publication Critical patent/UY28098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de anilinopirazol, a las composiciones farmacéuticas y a los métodos para tratar la diabetes y trastornos relacionados.
UY28098A 2002-11-27 2003-11-26 Derivados de anilinopirazol útiles en el tratamiento de la diabetes UY28098A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
UY28098A1 true UY28098A1 (es) 2004-06-30

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28098A UY28098A1 (es) 2002-11-27 2003-11-26 Derivados de anilinopirazol útiles en el tratamiento de la diabetes

Country Status (16)

Country Link
US (2) US7265144B2 (es)
EP (1) EP1567517A1 (es)
JP (1) JP2006510728A (es)
KR (1) KR20050085170A (es)
AR (1) AR042067A1 (es)
AU (2) AU2003295890A1 (es)
BR (1) BR0316723A (es)
CA (1) CA2507186A1 (es)
HN (1) HN2003000379A (es)
MX (1) MXPA05004621A (es)
MY (1) MY141528A (es)
PE (1) PE20040907A1 (es)
PL (1) PL377164A1 (es)
TW (1) TW200418803A (es)
UY (1) UY28098A1 (es)
WO (2) WO2004050650A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750698A4 (en) * 2004-05-20 2010-06-02 Bayer Pharmaceuticals Corp 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
SI1860098T1 (sl) 2005-03-16 2013-03-29 Toyama Chemical Co., Ltd. Nov derivat antranilne kisline ali sol le-tega
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
CA2620425A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
EP2049493B1 (en) 2006-07-31 2012-03-21 Cadila Healthcare Limited Compounds suitable as modulators of hdl
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US20100016396A1 (en) * 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
US20110034521A1 (en) * 2007-09-28 2011-02-10 Alan Jacobson Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
US20110190285A1 (en) * 2008-09-19 2011-08-04 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
CA2736434A1 (en) 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
US9394269B2 (en) 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
CA3066680C (en) * 2017-05-26 2022-04-12 Dongfang Shi Urat1 inhibitor for increasing uric acid excretion
US11312722B2 (en) * 2019-05-08 2022-04-26 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT649407A (es) 1960-04-14
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
JPH07500116A (ja) 1992-03-26 1995-01-05 ダウエランコ 殺菌剤としてのｎ−複素環式ニトロアニリン
JPH10509708A (ja) * 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
AR042067A1 (es) 2005-06-08
WO2004050651A1 (en) 2004-06-17
JP2006510728A (ja) 2006-03-30
BR0316723A (pt) 2005-10-18
KR20050085170A (ko) 2005-08-29
WO2004050650A1 (en) 2004-06-17
US20080064734A1 (en) 2008-03-13
TW200418803A (en) 2004-10-01
EP1567517A1 (en) 2005-08-31
US7265144B2 (en) 2007-09-04
AU2003295890A1 (en) 2004-06-23
CA2507186A1 (en) 2004-06-17
HK1087103A1 (zh) 2006-10-06
US20040157904A1 (en) 2004-08-12
AU2003297565A1 (en) 2004-06-23
PL377164A1 (pl) 2006-01-23
MXPA05004621A (es) 2005-06-08
HN2003000379A (es) 2005-12-20
MY141528A (en) 2010-05-14
PE20040907A1 (es) 2005-01-27

Similar Documents

Publication Publication Date Title
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
UY28376A1 (es) Agentes terapéuticos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY28144A1 (es) Agentes terapéuticos
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY27918A1 (es) Derivados de benzodioxol
PA8544901A1 (es) Derivados de oxazol
UY28691A1 (es) Derivados de difenilazetidona
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
PA8555401A1 (es) Derivados de quinolina
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PA8531701A1 (es) Derivados de pirimidina
UY28377A1 (es) Agentes terapeuticos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
ECSP055844A (es) Nuevos compuestos triciclicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160120